Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Minocin® (Minocycline) for Injection in Healthy Adults
Status:
Completed
Trial end date:
2018-02-08
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single and multiple
ascending dose study of the safety, tolerability, and pharmacokinetics of Minocin®
(minocycline) for injection in healthy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Collaborators:
Innovative Medicines Initiative The Medicines Company Universitätsklinikum Köln